Drug intelligence / Profile preview

MAK Immune Cells

Development stage: Phase 2
Lead developer: Beijing Tuohua Weiye Biotechnology
Modality: Cell Therapies
Administration: Intravenous

Overview

MAK Immune Cells are a type of adoptive cell therapy consisting of a population of mixed-activated killer cells, primarily characterized by the phenotypes CD3-CD16+CD56+ (Natural Killer cells) and CD3+CD56+ (Natural Killer T cells). These cells are derived from peripheral blood mononuclear cells or umbilical cord blood, expanded and cultured in vitro, and then administered intravenously. The therapy is designed to leverage the inherent tumor-killing activity of these immune cells to target and eliminate cancer cells. It is currently under investigation for the treatment of various malignancies, including primary hepatocellular carcinoma, stage IV pancreatic cancer, and cholangiocarcinoma.

Other names: Mixed-activated Killer cells

Beyond the preview

Go deeper on MAK Immune Cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAK Immune Cells.

Explore the full profile